These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 32764200)

  • 21. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
    Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
    Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
    Schlickeiser S; Schwarz T; Steiner S; Wittke K; Al Besher N; Meyer O; Kalus U; Pruß A; Kurth F; Zoller T; Witzenrath M; Sander LE; Müller MA; Scheibenbogen C; Volk HD; Drosten C; Corman VM; Hanitsch LG
    Front Immunol; 2020; 11():628971. PubMed ID: 33584731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
    Castillo-Olivares J; Wells DA; Ferrari M; Chan ACY; Smith P; Nadesalingam A; Paloniemi M; Carnell GW; Ohlendorf L; Cantoni D; Mayora-Neto M; Palmer P; Tonks P; Temperton NJ; Peterhoff D; Neckermann P; Wagner R; Doffinger R; Kempster S; Otter AD; Semper A; Brooks T; Albecka A; James LC; Page M; Schwaeble W; Baxendale H; Heeney JL
    Front Immunol; 2021; 12():748291. PubMed ID: 34867975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays.
    Rikhtegaran Tehrani Z; Saadat S; Saleh E; Ouyang X; Constantine N; DeVico AL; Harris AD; Lewis GK; Kottilil S; Sajadi MM
    PLoS One; 2020; 15(11):e0237828. PubMed ID: 33137138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays.
    Weidner L; Gänsdorfer S; Unterweger S; Weseslindtner L; Drexler C; Farcet M; Witt V; Schistal E; Schlenke P; Kreil TR; Jungbauer C
    J Clin Virol; 2020 Aug; 129():104540. PubMed ID: 32652475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
    Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
    Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
    Ha B; Jadhao S; Hussaini L; Gibson T; Stephens K; Salazar L; Ciric C; Taylor M; Rouphael N; Edupuganti S; Rostad CA; Tompkins SM; Anderson EJ; Anderson LJ
    Microbiol Spectr; 2021 Oct; 9(2):e0045821. PubMed ID: 34494855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
    Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
    J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
    Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
    Front Immunol; 2021; 12():739037. PubMed ID: 34594341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
    Robbiani DF; Gaebler C; Muecksch F; Lorenzi JCC; Wang Z; Cho A; Agudelo M; Barnes CO; Gazumyan A; Finkin S; Hägglöf T; Oliveira TY; Viant C; Hurley A; Hoffmann HH; Millard KG; Kost RG; Cipolla M; Gordon K; Bianchini F; Chen ST; Ramos V; Patel R; Dizon J; Shimeliovich I; Mendoza P; Hartweger H; Nogueira L; Pack M; Horowitz J; Schmidt F; Weisblum Y; Michailidis E; Ashbrook AW; Waltari E; Pak JE; Huey-Tubman KE; Koranda N; Hoffman PR; West AP; Rice CM; Hatziioannou T; Bjorkman PJ; Bieniasz PD; Caskey M; Nussenzweig MC
    Nature; 2020 Aug; 584(7821):437-442. PubMed ID: 32555388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
    Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
    Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays.
    Yang HS; Racine-Brzostek SE; Lee WT; Hunt D; Yee J; Chen Z; Kubiak J; Cantu M; Hatem L; Zhong E; D'Ambrosio D; Chadburn A; Westblade L; Glesby M; Loda M; Cushing MM; Zhao Z
    Clin Chim Acta; 2020 Oct; 509():117-125. PubMed ID: 32505774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
    Iyer AS; Jones FK; Nodoushani A; Kelly M; Becker M; Slater D; Mills R; Teng E; Kamruzzaman M; Garcia-Beltran WF; Astudillo M; Yang D; Miller TE; Oliver E; Fischinger S; Atyeo C; Iafrate AJ; Calderwood SB; Lauer SA; Yu J; Li Z; Feldman J; Hauser BM; Caradonna TM; Branda JA; Turbett SE; LaRocque RC; Mellon G; Barouch DH; Schmidt AG; Azman AS; Alter G; Ryan ET; Harris JB; Charles RC
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
    Ni L; Ye F; Cheng ML; Feng Y; Deng YQ; Zhao H; Wei P; Ge J; Gou M; Li X; Sun L; Cao T; Wang P; Zhou C; Zhang R; Liang P; Guo H; Wang X; Qin CF; Chen F; Dong C
    Immunity; 2020 Jun; 52(6):971-977.e3. PubMed ID: 32413330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
    Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
    Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
    Ripperger TJ; Uhrlaub JL; Watanabe M; Wong R; Castaneda Y; Pizzato HA; Thompson MR; Bradshaw C; Weinkauf CC; Bime C; Erickson HL; Knox K; Bixby B; Parthasarathy S; Chaudhary S; Natt B; Cristan E; El Aini T; Rischard F; Campion J; Chopra M; Insel M; Sam A; Knepler JL; Capaldi AP; Spier CM; Dake MD; Edwards T; Kaplan ME; Scott SJ; Hypes C; Mosier J; Harris DT; LaFleur BJ; Sprissler R; Nikolich-Žugich J; Bhattacharya D
    Immunity; 2020 Nov; 53(5):925-933.e4. PubMed ID: 33129373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.
    Harvala H; Mehew J; Robb ML; Ijaz S; Dicks S; Patel M; Watkins N; Simmonds P; Brooks T; Johnson R; Gopal R; Roberts DJ; Zambon M;
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.
    Farrugia A
    Transfus Clin Biol; 2020 Aug; 27(3):167-168. PubMed ID: 32563550
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.